Ontario Oncology Clinics Faced a Steady Expansion in Visit Volume
Outpatient medical oncology services in Ontario absorbed a much larger share of cancer care between 2015 and 2022, even though the rise in incident cancer cases looked modest on paper. In a population-based cohort of adults diagnosed with one of seven common solid tumors, the total number of new cases increased from 39,688 in 2015 to 45,011 in 2022. Over the same interval, the proportion of newly diagnosed patients who had a consultation with a medical oncologist also increased, with the strongest contribution coming from the very large breast, lung, colon, rectal, melanoma, pancreas, and prostate cancer populations tracked in the registry.
The practical pressure on clinics came not from incidence alone, but from the cascade that follows an oncology consultation. Each additional patient who enters the system tends to generate repeated visits, treatment planning, toxicity surveillance, response assessment, and regimen changes. In modern cancer care, a single diagnosis can quickly become a sequence of outpatient encounters that stretches across months and often years.
First-Year Follow-Up Drove the Largest Increase in Workload
The most important signal was the difference between incident caseload and actual service use. Across the seven tumors, the observed changes translated into 3,589 more consultations and 43,193 more follow-up visits annually during the first year after initial medical oncology consultation. Systemic therapy visits rose by 36,185 during that same first year. Utilization remained high in the second year as well, showing that the burden did not end once the initial treatment plan was written.
That pattern reflects the structure of contemporary oncology practice. Patients now spend more time in active outpatient management because treatment is more continuous, more individualized, and more closely monitored than in earlier eras. Oral anticancer agents, maintenance approaches, immunotherapy, biomarker-directed regimens, and longer survivorship all keep patients in the ambulatory system longer. Even when hospitalization decreases, clinic intensity can increase.
The growth in follow-up volume matters because follow-up is where the work of oncology often accumulates. Dose adjustments, laboratory review, adverse-event triage, symptom management, scan interpretation, and treatment sequencing all occur there. The registry data show that the system’s burden is being driven by repeated contact rather than by a simple rise in first visits.
Pancreatic Cancer Remained a High-Consultation Outlier
Pancreatic cancer stood apart from the rest of the cohort. The proportion of new patients with a medical oncology consult reached 19.2%, far above the low single-digit increases seen across the broader diagnosis groups. This is clinically consistent with the aggressiveness of the disease, the urgency of systemic treatment decisions, and the limited window for intervention after diagnosis.
Even so, the study’s broader message did not depend on pancreas cancer alone. The absolute numbers across the more common solid tumors were large enough to reshape outpatient workloads at the population level. A small percentage shift applied to a large cancer population can produce a substantial downstream increase in staffing demand, chair time, physician availability, and administrative support.
Why Incident Cases Miss the Real Work of Cancer Care
Many workforce models still anchor planning to new diagnosis counts, but that approach captures only the entry point to oncology care. It does not account for how often patients return, how long they remain under active follow-up, or how frequently systemic therapy requires monitoring and modification. A system that sees more patients through diagnosis and treatment will feel the impact most acutely in outpatient clinics, where the bulk of longitudinal cancer management occurs.
The first two years after consultation are particularly important because they capture the period of greatest therapeutic intensity for many patients. In solid tumors, this is when adjuvant therapy, first-line metastatic treatment, switching of regimens, and surveillance converge. The observed rise in visits during that interval points to a heavier clinical load even when incidence appears to move only gradually.
Population Growth in Visits Has Direct Staffing Consequences
A rise of this scale changes how oncology services must be organized. More follow-up visits mean more room turnover, more coordination with pharmacy and infusion services, and more clinician time spent on assessment rather than on new patient intake. The clinical center of gravity shifts toward sustained management, which is harder to absorb without flexible staffing models.
Workforce planning based only on incident caseload will underestimate the real demand created by modern systemic therapy. The outpatient oncologist is now managing a larger cohort, for longer periods, and with a more complex array of treatments and toxicities. Those pressures are visible in the Ontario data even without relying on any single tumor type.
Population-Level Data Point to a Need for New Workforce Models
The cohort included 332,604 patients across the seven target cancers, giving the analysis enough breadth to reflect system-wide behavior rather than a narrow institutional pattern. Administrative data captured both incidence and service use, allowing the study to connect diagnosis trends with downstream utilization. That design is especially relevant for health-system planning because it measures what clinics actually deliver, not just how many patients appear on a registry list.
The central conclusion is straightforward: outpatient medical oncology utilization rose substantially between 2015 and 2022, and the rise was driven by more consultations, more follow-up, and more systemic therapy visits. The growth was not evenly distributed across diagnoses, but the overall trajectory was unmistakable. Ontario’s oncology system now needs workforce models that account for longitudinal care intensity, not simply first-contact volume.
The analysis does not answer how different treatment eras, tumor biology, or regional practice variation contributed to the expansion. It also does not separate visits by treatment intent, regimen type, or stage at diagnosis. Those gaps leave open the next layer of planning questions, but they do not change the operational signal already visible in the outpatient record: cancer care has become more visit-intensive, and staffing formulas built around incident cases alone will miss the load now carried by medical oncology clinics.